BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33425024)

  • 1. A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors.
    Forsythe A; Zhang W; Phillip Strauss U; Fellous M; Korei M; Keating K
    Ther Adv Med Oncol; 2020; 12():1758835920975613. PubMed ID: 33425024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis.
    Lassen U; Bokemeyer C; Garcia-Foncillas J; Italiano A; Vassal G; Paracha N; Marian M; Chen Y; Linsell L; Abrams K
    JCO Precis Oncol; 2023 Jun; 7():e2200651. PubMed ID: 37384865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes.
    Chetty R
    J Clin Pathol; 2019 Mar; 72(3):187-190. PubMed ID: 30636697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
    Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world challenges in undertaking
    Poh A; Sammour A; Mathai J; Peverall J; Van Vliet C; Asadi K; Parakh S
    J Thorac Dis; 2023 Jul; 15(7):3811-3817. PubMed ID: 37559603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
    Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
    Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
    Forschner A; Forchhammer S; Bonzheim I
    J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
    Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM
    JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.
    Westphalen CB; Krebs MG; Le Tourneau C; Sokol ES; Maund SL; Wilson TR; Jin DX; Newberg JY; Fabrizio D; Veronese L; Thomas M; de Braud F
    NPJ Precis Oncol; 2021 Jul; 5(1):69. PubMed ID: 34285332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
    Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
    Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
    Elfving H; Broström E; Moens LNJ; Almlöf J; Cerjan D; Lauter G; Nord H; Mattsson JSM; Ullenhag GJ; Strell C; Backman M; La Fleur L; Brunnström H; Botling J; Micke P
    Lung Cancer; 2021 Jan; 151():53-59. PubMed ID: 33310622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting.
    Bazhenova L; Lokker A; Snider J; Castellanos E; Fisher V; Fellous M; Nanda S; Zong J; Keating K; Jiao X
    Target Oncol; 2021 May; 16(3):389-399. PubMed ID: 33893941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncogenic roles of NTRK fusions and methods of molecular diagnosis.
    Aref-Eshghi E; Lin F; Li MM; Zhong Y
    Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of
    Koopman B; Kuijpers CCHJ; Groen HJM; Timens W; Schuuring E; Willems SM; van Kempen LC
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
    Farago AF; Taylor MS; Doebele RC; Zhu VW; Kummar S; Spira AI; Boyle TA; Haura EB; Arcila ME; Benayed R; Aisner DL; Horick NK; Lennerz JK; Le LP; Iafrate AJ; Ou SI; Shaw AT; Mino-Kenudson M; Drilon A
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30215037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors.
    Zhu L; Hobbs B; Roszik J; Holla V; Hong DS
    Invest New Drugs; 2022 Feb; 40(1):157-162. PubMed ID: 34341905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.